John Burn-Murdoch

And I would say there's decent evidence that living standards for those in the bottom 10% of the US have also been doing reasonably well over the over the relatively recent years, certainly better than the bottom 10% of the UK.

So yeah, I understand why the existence of the first trillionaire

causes so much anger and sense of injustice.

But my hope would be that regulation, redistribution ensures that as broad a section of society as possible can still benefit from this.

Thank you so much for having me.

This BBC podcast is supported by ads outside the UK.

Hello and welcome to Your Radical Questions, where I put your questions to one of our radical guests.

This is your chance to engage directly with the brilliant minds that we have on this podcast and ask them about their ideas for the future.

My name's John Byrne Murdoch, standing in for them all this week.

I'm a columnist and chief data reporter for the Financial Times.

I've just finished up a brilliant conversation with Sir John Bell, who is Emeritus Regis Professor of Medicine at Oxford University.

And if you haven't heard that conversation yet, I'd encourage you to go and listen.

Professor Sir John has advised the UK government on life sciences, pharmaceutical strategy and COVID testing and played a pivotal role in the development of the AstraZeneca COVID-19 vaccine during the pandemic.

He's currently a partner at Population Health Partners, a firm focused on investing in and advising life science companies.

and he previously served on the board of pharmaceutical company Roche.

And he joins me now.

Welcome back, Professor Sir John Bell.

Yeah, it's a pleasure to be here.

Well, we've got a really interesting question to start off with, which I think gets into the nitty gritty of some of this stuff.

So when we're talking about personalised medicine, the listener Ruxandra asks, one of the big questions for her is how do these truly personalised therapies fit alongside our current regulatory framework around clinical trials?